Loading insider details...
Beta
Latest Form 4 (Oct 3, 2026): Sale of 600 SYRE shares, $53.5K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 3, 2026 | Spyre Therapeutics, Inc. (SYRE) | Sale | 600 | $53.5K |
| Sep 4, 2026 | Spyre Therapeutics, Inc. (SYRE) | Sale | 2,500 | $215.9K |
| Aug 6, 2026 | Spyre Therapeutics, Inc. (SYRE) | Sale | 800 | $75.2K |
| Jul 3, 2026 | Spyre Therapeutics, Inc. (SYRE) | Sale | 10,176 | $889.8K |
| Jun 4, 2026 | Spyre Therapeutics, Inc. (SYRE) | Sale | 3,557 | $246.9K |
| May 2, 2026 | Spyre Therapeutics, Inc. (SYRE) | Sale | 5,300 | $368.6K |
| Apr 4, 2026 | Spyre Therapeutics, Inc. (SYRE) | Sale | 12,344 | $607.3K |
| Mar 25, 2026 | Damora Therapeutics, Inc. (DMRA) | Grant/Award | 37,313 | n/a |
| Mar 4, 2026 | Spyre Therapeutics, Inc. (SYRE) | Sale | 5,900 | $246.2K |
| Feb 5, 2026 | Spyre Therapeutics, Inc. (SYRE) | Sale | 957 | $30.5K |